| Trial ID | NCT04883255 |
| Status | Recruiting |
| Condition | HIV-1-infection |
| Intervention | 10 mg ฮ9-tetrahydrocannabinol (THC) |
This trial addresses a critical knowledge gap in HIV care where cannabis use is widespread but poorly understood clinically. Given cannabis’s documented anti-inflammatory properties and HIV’s chronic inflammatory burden, understanding cognitive effects could inform evidence-based prescribing recommendations for this vulnerable population.
This observational study (NCT04883255) is examining how 10mg THC affects cognition and endocannabinoid system function in people with HIV-1 infection. The trial is currently recruiting participants to assess cognitive performance, decision-making, and biomarkers of endocannabinoid activity. Primary endpoints include neuropsychological testing and inflammatory markers, with secondary measures examining risk-taking behaviors and attention.
“If this trial demonstrates cognitive benefits at therapeutic THC doses, it could provide the evidence base I need to confidently recommend specific cannabis formulations for HIV patients experiencing cognitive symptoms. Currently, I’m prescribing based on limited data and patient reports rather than controlled evidence.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This trial item was assembled from normalized source metadata and pipeline scoring.
